eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that Steve Worland, Ph.D., president, and chief executive officer of eFFECTOR, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14th at 10:40 am ET.
Related news for (EFTR)
- eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
- eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
- eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
- eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer